

ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)

To the Editor,

A novel strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named by the International Committee on Taxonomy of Viruses (ICTV),¹ has recently emerged and caused an infectious disease. This disease is referred to as the "coronavirus disease 2019" (COVID-19) by the World Health Organization (WHO).²

The US Centers for Disease Control and Prevention (CDC) have proposed that "People with moderate to severe asthma may be at higher risk of getting very sick from COVID-19. COVID-19 can affect your respiratory tract (nose, throat, lungs), cause an asthma attack and possibly lead to pneumonia and acute respiratory disease." (May 24, 2020). (<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/asthma.html>) On the other hand, in the UK, NICE proposes rapid guidelines for severe asthma (<https://www.guidelines.co.uk/covid-19-rapid-guideline-severe-asthma/455275.article>).

An ARIA-EAACI statement has been devised to make recommendations on asthma, and not necessarily on severe asthma, based on a consensus from its members.

It is difficult in many studies to clearly assess the prevalence of asthma on COVID-19 since most patients are older adults and probably have multimorbidities. Most studies do not clarify whether asthmatic patients with COVID-19 have isolated asthma or asthma as a multimorbidity, particularly in the context of hypertension, obesity and diabetes. In particular, obesity is a significant risk factor for COVID-19 and its severity,³ and may be intertwined with asthma.

In some studies, showing data mostly on critically ill patients, there does not appear to be an increased prevalence of asthma.⁴⁻⁷ In Wuhan, the prevalence of asthma in COVID-19 patients was 0.9%, markedly lower than that of the general adult population of this city.⁸ Differently, in New York, among 5,700 hospitalized patients with COVID-19, asthma prevalence was 9% and COPD 4.5%.⁹ In California, 7.4% of the 377 hospitalized patients had asthma or COPD.¹⁰ The US CDC reported that between March 1st and 30th 2020, among COVID-NET hospitals from 99 counties and 14 states (an open source neural network for COVID-19 infection), chronic lung disease (primarily asthma) was the second most prevalent comorbid condition for hospitalized patients aged 18-49 years with laboratory-confirmed COVID-19.¹¹ Among the 17% of COVID-19-positive patients with an underlying history of asthma, the incidence

was at its highest in younger adults (27% in the 18- to 49-year-old group). The UK experience on over 20, 133 hospitalized cases shows that 14% of admissions were patients with asthma.¹² In the OpenSAFELY Collaborative Study (UK), an increased risk of severe COVID-19, including death, was found in patients with asthma, particularly related with a recent use of oral corticosteroid.¹³ A review with all identified studies up to 5 May 2020 is available.¹⁴ However, low socioeconomic status, obesity, non-white ethnicity, chronic respiratory disease and diabetes had stronger signals.

Some anti-asthma medications, such as ciclesonide, might have a beneficial effect on COVID-19.¹⁵

Thus, whether patients with asthma are at a higher or lower risk of acquiring COVID-19 may depend on geography, age, other multimorbidities, different air quality,¹⁶ genetic predispositions, ethnicity, social behaviour, access to health care or other factors. Moreover, the current information is obtained mainly from hospitalization or intensive care unit data. Real-life data in a non-selected population of asthmatics are needed to better understand the links between asthma and SARS-Cov-2 in terms of both incidence and severity.

Asthma does not seem to be a risk factor for severe COVID-19 but patients treated with oral corticosteroids may be at a higher risk of severe COVID-19.¹⁴ However, a large study is needed to fully appreciate the relationship between COVID-19 and severe asthma.

According to the IPCRG (International Primary Care Respiratory Group), patients are still struggling to differentiate their symptoms between asthma flare-ups and COVID-19. They may therefore delay seeking care for asthma or COVID-19. Interestingly, clarity does not appear to have improved as the weeks have passed. People have recurrences or waves of repeated symptoms, and it is difficult to understand whether the symptoms are related to an asthma exacerbation or to COVID-19.

According to the IPCRG, many clinicians tend to prescribe antibiotics to people who they believe are having asthma exacerbations "just to be safe." They focus on the potential infection element of the trigger more than the asthma management itself. It would seem that COVID-19 might exacerbate this behaviour, not improve it.

In areas where COVID-19 is prevalent, GPs are still very concerned about oral—and, to a certain degree, inhaled—corticosteroids, possibly because they use remote models of care. They are

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. *Allergy* published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd




FIGURE 1 Geographic representation of the experts

reluctant to prescribe higher doses of ICS or OCS as they fear they cannot tell the difference between a flare-up and COVID-19.

The extent of expression in the upper and lower airways of the SARS-CoV-2 entry receptors, angiotensin-converting enzyme 2

(ACE2) and TMPRSS2, might impact the clinical severity of COVID-19. ACE-2 was found to be decreased in patients with allergic asthma¹⁷ or in those receiving inhaled corticosteroids.¹⁸ These data suggest that this expression may be a potential contributor, among

- 1 In areas where COVID-19 is prevalent, screening protocols for COVID-19 should be applied to anyone having worsening respiratory symptoms, and personal protective equipment should be used.
- 2 In areas where COVID-19 is prevalent, lung function testing procedures should be postponed if not deemed absolutely necessary; portable personal devices measuring PEF and FEV1 can be used in the meantime to monitor asthma control using the telemedicine approach.
- 3 In accordance with the Global Initiative for Asthma (GINA) (<https://ginasthma.org/recommendations-for-inhaled-asthma-controller-medications/>), patients with asthma should not stop their prescribed inhaled corticosteroid controller medication (or prescribed oral corticosteroids). Stopping inhaled corticosteroids may have serious consequences.
- 4 Long-term oral corticosteroids may sometimes be required to treat severe asthma, and it may be dangerous to stop them suddenly (GINA).
- 5 Oral steroids should continue to be used to treat severe asthma exacerbations.
- 6 In patients infected by SARS-CoV-2 (symptomatic or asymptomatic), nebulization (which increases the risk of deposition of the virus into the lower airways) should be replaced by spacers of large capacity.
- 7 In accordance with the NICE, in non-SARS-CoV-2 infected patients, we propose(<https://www.nice.org.uk/guidance/ng166/chapter/3-Treatment#patients-having-biological-treatment>):
 - To continue biologics because there is no evidence that biological therapies for asthma suppress immunity
 - If the patient usually attends a hospital for biological treatments, to think about if he/she can be trained to self-administer or could be treated at a community clinic or at home
 - To carry out routine monitoring of biological treatment remotely if possible
- 8 In SARS-CoV-2-infected patients, in accordance with the EAACI, we propose to cease the treatment until resolution of the disease is established. Thereafter, the administration of the biological should be re-initiated.

TABLE 1 ARIA-EAACI statement

TABLE 2 ARIA-EAACI research questions

Real-world studies need to be carried out on a large number of unselected patients to assess	
1	Impact of COVID-19 on asthma control
2	Impact of COVID-19 respiratory symptoms on severe asthma
3	Impact of severe asthma on COVID-19 occurrence and/or severity of pneumonia
4	Impact of multimorbidities on asthmatic patients for the control of asthma during COVID-19
5	Serologic studies should be performed to assess whether seroconversion and its duration differ in asthmatic and non-asthmatic subjects
6	The phenotype of asthma (allergic, neutrophilic, age....) should be studied
7	In adult patients, studies should clarify whether asthmatic patients with COVID-19 have isolated asthma or asthma in the context of multimorbidity, particularly in the context of high blood pressure, obesity and diabetes mellitus
8	Role of pollen season on COVID-19 severity

several other factors, to reduced COVID-19 severity in patients with T2 inflammation.^{17,19} However, ACE-2 expression in asthma patients was increased in African Americans, in males and in association with diabetes.

Finally, a recent study which analysed the nasal transcriptome of 695 children suggested that the strongest determinants of airway ACE2 and TMPRSS2 expression are T2 inflammation and viral-induced interferon inflammation. However, this study specifically showed that T2 inflammation (via IL-13) impacted differentially on ACE2 and TMPRSS2, with a T2-high phenotype being associated with a highly significant decrease in the former and a significant decrease in the latter receptor. Thus, although SARS-CoV-2-specific analyses and experiments are lacking, the differential effects of T2-inflammation on ACE2 and TMPRSS2 reported in this study warrant further research on whether T2-high and T2-low asthma phenotypes may be associated with differential susceptibility to severe COVID-19.

The first author developed seven recommendations that were sent for comment to 105 experts around the world. 69 answers were received within 48 hours, and the comments were considered. Where experts suggested modification of the recommendations, a discussion was initiated and recommendations modified until consensus was reached. After these modifications, a total of 9 recommendations were proposed for a second round. In the second round, 145 experts were invited to comment on and approve or reject the recommendations. 78 answers were received within 48 hours and, when an agreement of over 80/100 was reached, the question was included in the statement.

The same approach was used for the research questions. Two research needs were dropped.

The geographic distribution of the experts is given in Figure 1. They were from 43 countries.

ARIA-EAACI statement (Table 1).

ARIA-EAACI research questions (Table 2).

This view is pragmatic, cautious and based upon expert opinion. However, it is likely to require modifications as further evidence is

gathered. These recommendations are conditional and should be adapted regularly on the basis of evolving clinical evidence.

ACKNOWLEDGMENT

Open access funding enabled and organized by Projekt DEAL.

CONFLICTS OF INTEREST

IA reports and Associate Editor of *Allergy*. CA reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne-Center for Allergy Research and Education, European Commission's Horizon's 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, Scibase, advisory role in Sanofi/Regeneron. IA reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, AstraZeneca, Stallergenes, Abbott, Bial. EB is a member of the Science Committee and Board of the Global Initiative for Asthma (GINA). SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. JPB reports grants from AstraZeneca, Boston Scientific, GSK, Hoffman La Roche, Ono Pharma, Novartis, Sanofi, Takeda, Boehringer-Ingelheim, Merck, personal fees from AstraZeneca, GSK, Merck, Metapharm, Novartis, Takeda, other from AstraZeneca, Boehringer-Ingelheim, GSK, Merck, Novartis. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, other from KYomed-Innov. RB reports grants to Mainz University and personal fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Roche, as well as personal fees from AstraZeneca, Chiesi, Cipla, Sanofi, and Teva. VC reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermo Fisher, Stallergenes. RSC reports grants from NIAID, CoFAR, Aimmune, DBV Technologies, Astellas, Regeneron, an Advisory member for Alladapt, Genentech, Novartis, and receives personal fees from Before Brands. AC reports grants and personal fees from GSK, SANOFI, Boehringer-Ingelheim, Astrazeneca, Mantecorp, MYLAN, Novartis, personal fees and non-financial support from CHIESI. SdG reports personal fees from AstraZeneca, Chiesi,

Menarini, grants and personal fees from GSK, Novartis. DH reports personal fees from AstraZeneca, Chiesi, GSK, Pfizer, personal fees and non-financial support from Boehringer Ingelheim, Novartis. TE reports other from DBV, Regeneron, grants from Innovation fund Denmark and Co-I or scientific lead in three investigator initiated oral immunotherapy trials supported by the Allergy and Anaphylaxis Program Sickkids and serve as associate editor for Allergy. Advisory board ALK. JF reports personal fees from AstraZeneca, GSK, undipharma, grants and personal fees from Novartis. MG reports grants and personal fees from Elpen, Novartis, Menarini, grants from Galapagos, personal fees from BMS, MSD. TH reports personal fees from GSK, Mundipharma, OrionPharma. MH reports personal fees and non-financial support from GlaxoSmithKline, personal fees from Astrazeneca, Novartis, Roche, Sanofi, Teva. JCI reports personal fees from Faes Farma, Eurofarma Argentina, other from Laboratorios Casasco, Sanofi. GJ reports grants from AstraZeneca, Chiesi, personal fees from Bayer, Eureka vzw, Teva, grants and personal fees from GlaxoSmithKline. MJ reports personal fees from ALK-Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, from HAL, Astra-Zeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, Chiesi, LK reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, grants from Lofarma, AstraZeneca, GSK, Inmunotk and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO-BV GPA, EAACI. PK reports personal fees from Astra, Boehringer Ingelheim, Berlin Chemie Menarini, GSK, Lekam, Novartis, Polpharma, Mylan, Orion, Teva, Adamed. VK reports personal fees from GSK, non-financial support from StallergenGreer, AstraZeneca, Norameda, DIMUNA. DLL reports personal fees from Allakos, Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB, Alakos, Gossamer, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi, Purina institute. RL reports grants and personal fees from AZ, GSK, Novartis, grants from Chiesi, JM reports personal fees and other from SANOFI-GENZYME & REGENERON, NOVARTIS, ALLAKOS, grants and personal fees from MYLAN Pharma, URIACH Group, personal fees from Mitsubishi-Tanabe, Menarini, UCB, AstraZeneca, GSK, from MSD, outside the submitted work. KN reports grants and other from NIAID, FARE, personal fees and other from Regeneron, grants from EAT, other from Sanofi, Astellas, Nestle, BeforeBrands, Alladapt, ForTra, Genentech, Almmune Therapeutics, DBV Technologies, personal fees from Astrazeneca, ImmuneWorks, Cour Pharmaceuticals, grants from Allergenix, Ukko Pharma, Novartis, AnaptysBio, Adare Pharmaceuticals, Stallergenes-Greer, NHLBI, NIEHS, EPA, WAO Center of Excellence, Iggenix, Probio, Vedanta, Centecor, Seed, Immune Tolerance Network, NIH,; In addition, Dr Nadeau has a patent Inhibition of Allergic Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent Special Oral Formula for Decreasing Food Allergy Risk and Treatment for Food Allergy pending, a patent

Basophil Activation Based Diagnostic Allergy Test pending, a patent Granulocyte-based methods for detecting and monitoring immune system disorders pending, a patent Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders pending, a patent Mixed Allergen Compositions and Methods for Using the Same pending, and a patent Microfluidic Device and Diagnostic Methods for Allergy Testing Based on Detection of Basophil Activation pending. YO reports personal fees from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Eizai Co., Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm. ROB reports grants and personal fees from AstraZeneca, GSK, grants from Novartis, Medimmune, Bayer. YO reports personal fees from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Eizai Co., Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm, outside the submitted work. NP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolyptos International SA, Capricare. OP reports grants and personal fees from Anergis SA, ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, grants from Biomay, Glaxo Smith Kline Circassia, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA²LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL, NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, streamedup! GmbH. FP reports sanofi, novartis, teva, astrazeneca, glaxosmithkline, menarini, mundipharma, guidotti, malesci, chiesi, valeas, allergy therapeutics, almirall, personal fees from boehringer Ingelheim. FR reports personal fees from AstraZeneca, Novartis, Lusomedicamenta, Sanofi, GSK. JS reports other from MEDA, grants and personal fees from SANOFI, personal fees from GSK, NOVARTIS, ASTRA ZENECA, MUNDIPHARMA, FAES FARMA. JSchwarze reports personal fees from MYLAN, outside the submitted work. ASheikh reports support of the Asthma UK Centre for Applied Research. RS reports grants from São Paulo Research Foundation, MSD, grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca, Chiesi, Boehringer Ingelheim. IT reports grants from GSK Hellas, ELPEN, personal fees from Boehringer Ingelheim, Novartis, Astra Zeneca, GSK. TZ reports Organizational affiliations: Committee member: WHO-Initiative "Allergic Rhinitis and Its Impact on Asthma" (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GA²LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). The other authors have no COI to declare.

Jean Bousquet^{1,2,3,4}

Marek Jutel⁵

Cezmi A. Akdis⁶ 

- Ludger Klimek⁷
 Oliver Pfaar⁸ 
 Kari C. Nadeau⁹ 
 Thomas Eiwegger¹⁰ 
 Anna Bedbrook⁴
 Ignacio J. Ansotegui¹¹
 Josep M. Anto^{12,13,14,15}
 Claus Bachert^{16,17,18,19} 
 Eric D. Bateman²⁰
 Kazi S. Bennoor²¹
 Elena Camelia Berghea^{22,23}
 Karl-Christian Bergmann^{1,2} 
 Hubert Blain^{24,25}
 Mateo Bonini^{26,27} 
 Sinthia Bosnic-Anticevich^{28,29}
 Louis-Philippe Boulet³⁰ 
 Luisa Brussino³¹
 Roland Buhl³²
 Paulo Camargos³³
 Giorgio Walter Canonica³⁴
 Victoria Cardona³⁵ 
 Thomas Casale³⁶ 
 Sharon Chinthrajah⁹
 Mübeccel Akdis⁶ 
 Tomas Chivato³⁷
 George Christoff³⁸
 Alvaro A. Cruz³⁹ 
 Wienczyslawa Czarlewski⁴⁰
 Stefano Del Giacco⁴¹
 Hui Du⁴²
 Yehia El-Gamal⁴³
 Wytske J. Fokkens^{44,45} 
 Joao A. Fonseca^{46,47,48,49}
 Yadong Gao⁴²
 Mina Gaga⁵⁰
 Bilun Gemiciglu⁵¹
 Maia Gotua⁵² 
 Tari Haahtela⁵³ 
 David Halpin⁵⁴
 Eckard Hamelmann⁵⁵ 
 Karin Hoffmann-Sommergruber⁵⁶
 Marc Humbert⁵⁷
 Nataliya Ilina⁵⁸
 Juan-Carlos Ivancevich⁵⁹
 Guy Joos⁶⁰
 Musa Khaitov⁵⁸
 Bruce Kirenga⁶¹
 Edward F. Knol⁶²
 Fanny W. Ko⁶³
 Seppo Koskinen⁶⁴
 Marek L. Kowalski⁶⁵
 Helga Kraxner⁶⁶
 Dmitry Kudlay⁵⁸ 
- Piotr Kuna⁶⁷
 Maciej Kupczyk⁶⁷
 Violeta Kvedariene^{68,69}
 Amir H. Abdul Latiff⁷⁰
 Lan T. Le⁷¹
 Michael Levin⁷² 
 Desiree Larenas-Linnemann⁷³ 
 Renaud Louis⁷⁴
 Mohammad R. Masjedi⁷⁵
 Erik Melén^{76,77}
 Florin Mihaltan⁷⁸
 Branislava Milenkovic⁷⁹
 Youssef Mohammad^{80,81}
 Mario Morais-Almeida⁸² 
 Joaquim Mulloj^{83,84}
 Leyla Namazova^{85,86}
 Hugo Neffen^{87,88}
 Elisabete Nunes⁸⁹
 Paul O'Byrne^{90,91}
 Robyn O'Hehir⁹²
 Liam O'Mahony⁹³
 Ken Ohta⁹⁴ 
 Yoshitaka Okamoto⁹⁵
 Gabrielle L. Onorato⁴
 Petr Panzner⁹⁶
 Nikos G. Papadopoulos⁹⁷ 
 Gianni Passalacqua⁹⁸ 
 Vincenzo Patella⁹⁹ 
 Ruby Pawankar¹⁰⁰
 Nhat Pham-Thi¹⁰¹
 Bernard Pigearias¹⁰²
 Todor A. Popov¹⁰³
 Francesca Puggioni³⁴
 Frederico S. Regateiro^{104,105,106}
 Giovanni Rolla³¹
 Menachem Rottem^{107,108}
 Boleslaw Samolinski¹⁰⁹
 Joaquin Sastre¹¹⁰ 
 Jurgen Schwarze¹¹¹
 Aziz Sheikh¹¹²
 Nicola Scichilone¹¹³
 Manuel Soto-Quiros¹¹⁴
 Manuel Soto-Martinez¹¹⁴
 Milan Sova¹¹⁵
 Stefania Nicola¹¹⁶
 Rafael Stelmach¹¹⁷
 Charlotte Suppli-Ulrik¹¹⁸
 Luis Taborda-Barata^{119,120}
 Teresa To¹²¹
 Peter-Valentin Tomazic¹²² 
 Sanna Toppila-Salmi⁵³ 
 Ioanna Tsiligianni^{123,124}
 Omar Usmani¹²⁵

- Arunas Valiulis^{126,127}
 Maria Teresa Ventura¹²⁸
 Giovanni Viegi^{129,130}
 Theodor Vontetsianos¹³¹
 De Yun Wang¹³²
 Sian Williams¹³³
 Gary W. K. Wong¹³⁴ 
 Arzu Yorgancioglu¹³⁵
 Mario Zernotti¹³⁶
 Mihaela Zidarn¹³⁷
 Torsten Zuberbier^{1,2} 
 Ioana Agache¹³⁸ 
- ¹Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
²Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany
³University Hospital Montpellier, Montpellier, France
⁴MACVIA-France, Montpellier, France
⁵Department of Clinical Immunology, Wrocław Medical University and ALL-MED Medical Research Institute, Wrocław, Poland
⁶Akdis M. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
⁷Center for Rhinology and Allergology, Wiesbaden, Germany
⁸Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany
⁹Stanford University School of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA
¹⁰The Hospital for Sick Children, Department of Paediatrics, Division of Clinical Immunology and Allergy, Food allergy and Anaphylaxis Program, The University of Toronto, Toronto, ON, Canada
¹¹Department of Allergy and Immunology, Hospital Quironsalud Bizkaia, Erandio, Spain
¹²Centre for Research in Environmental Epidemiology (CREAL), ISGlobAL, Barcelona, Spain
¹³IMIM (Hospital del Mar Research Institute), Barcelona, Spain
¹⁴Universitat Pompeu Fabra (UPF), Barcelona, Spain
¹⁵CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
¹⁶Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium
¹⁷International Airway Research Center, First Affiliated Hospital Guangzhou, Sun Yat-sen University, Guangzhou, China
¹⁸Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden
¹⁹Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden
²⁰Department of Medicine, University of Cape Town, Cape Town, South Africa
²¹Department of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh
²²Allergology and Clinical Immunology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
²³Clinical Emergency Hospital for Children MS Curie, Bucharest, Romania
²⁴Department of Geriatrics, Montpellier University Hospital, Montpellier, France
²⁵EA:2991, Euromov, University Montpellier, Montpellier, France
²⁶Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
²⁷National Heart and Lung Institute, Royal Brompton Hospital and Imperial College London, London, UK
²⁸Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia
²⁹Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia
³⁰Quebec Heart and Lung Institute, Laval University, Québec City, QC, Canada
³¹Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino and Maurizio Hospital, Torino, Italy
³²Department of Pulmonary Medicine, Mainz University Hospital, Mainz, Germany
³³Department of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil
³⁴Personalized Medicine Asthma and Allergy Clinic-Humanitas University and Research Hospital, IRCCS-Milano, Milano, Italy
³⁵Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron and ARADyAL research network, Barcelona, Spain
³⁶Division of Allergy/immunology, University of South Florida, Tampa, FL, USA
³⁷School of Medicine, University CEU San Pablo, Madrid, Spain
³⁸Faculty of Public Health, Medical University - Sofia, Sofia, Bulgaria
³⁹Fundação ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Brazil
⁴⁰Medical Consulting Czarlewski, Levallois, France
⁴¹Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital "Duilio Casula", University of Cagliari, Cagliari, Italy
⁴²Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China
⁴³Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt
⁴⁴Department of Otorhinolaryngology, Academic Medical Centers, AMC, Amsterdam, The Netherlands
⁴⁵EUFORCA, Brussels, Belgium
⁴⁶Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal

- ⁴⁷Allergy Unit, Instituto CUF Porto e Hospital CUF Porto, Porto, Portugal
- ⁴⁸Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
- ⁴⁹Faculdade de Medicina da Universidade do Porto, Porto, Portugal
- ⁵⁰7th Respiratory Medicine Department and Asthma Center, Athens Chest Hospital, Athens, Greece
- ⁵¹Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
- ⁵²Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia
- ⁵³Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
- ⁵⁴College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, UK
- ⁵⁵Klinik für Kinder- und Jugendmedizin, Kinderzentrum Bethel, Evangelisches Klinikum Bethel EvKB, University Bielefeld, Bielefeld, Germany
- ⁵⁶Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
- ⁵⁷Service de Pneumologie, Hôpital Bicêtre, Inserm UMR_S999, Université Paris-Sud, Le Kremlin Bicêtre, France
- ⁵⁸National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russia
- ⁵⁹Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina
- ⁶⁰Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
- ⁶¹Makerere University Lung Institute, Kampala, Uganda
- ⁶²Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
- ⁶³Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
- ⁶⁴Finnish Institute for Health and Welfare, Helsinki, Finland
- ⁶⁵Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland
- ⁶⁶Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Budapest, Hungary
- ⁶⁷Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
- ⁶⁸Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania
- ⁶⁹Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical medicine, Vilnius University, Vilnius, Lithuania
- ⁷⁰Allergy and Immunology Centre, Pantai Hospital, Kuala Lumpur, Malaysia
- ⁷¹University of Medicine and Pharmacy, Hochiminh City, Vietnam
- ⁷²Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa
- ⁷³Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico
- ⁷⁴Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 Research Group, Liege, Belgium
- ⁷⁵Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran
- ⁷⁶Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden
- ⁷⁷Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- ⁷⁸National Institute of Pneumology M Nasta, Bucharest, Romania
- ⁷⁹Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, Serbian Association for Asthma and COPD, University of Belgrade, Belgrade, Serbia
- ⁸⁰National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syria
- ⁸¹Syrian Private University-Damascus, Damas, Syria
- ⁸²Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal
- ⁸³Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, Barcelona, Spain
- ⁸⁴Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain
- ⁸⁵Scientific Centre of Children's Health Under the MoH, Moscow, Russia
- ⁸⁶Russian National Research Medical University Named Pirogov, Moscow, Russia
- ⁸⁷Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina
- ⁸⁸Argentina Center for Allergy and Immunology, Santa Fe, Argentina
- ⁸⁹Serviço de Pneumologia Hospital Central and Faculdade de Medicina Dr Eduardo Mondelane, Maputo, Mozambique
- ⁹⁰Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada
- ⁹¹Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
- ⁹²Department of Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University, and Alfred Health, Melbourne, Vic., Australia
- ⁹³Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland
- ⁹⁴National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- ⁹⁵Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan
- ⁹⁶Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic
- ⁹⁷Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK

- ⁹⁸Allergy and Respiratory Diseases, Ospedale Policlinico San Martino -University of Genoa, Genoa, Italy
- ⁹⁹Division of Allergy and Clinical Immunology, Department of Medicine, Agency of Health ASL Salerno, "Santa Maria della Speranza" Hospital, Salerno, Italy
- ¹⁰⁰Department of Pediatrics, Nippon Medical School, Tokyo, Japan
- ¹⁰¹Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Médicale des Armées), Bretigny, France
- ¹⁰²Société de Pneumologie de Langue Française, Espace Francophone de Pneumologie, Paris, France
- ¹⁰³University Hospital 'Sv Ivan Rilski', Sofia, Bulgaria
- ¹⁰⁴Allergy and Clinical Immunology Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- ¹⁰⁵Faculty of Medicine, Institute of Immunology, University of Coimbra, Coimbra, Portugal
- ¹⁰⁶Faculty of Medicine, ICBR - Coimbra Institute for Clinical and Biomedical Research, CIBB, University of Coimbra, Coimbra, Portugal
- ¹⁰⁷Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel
- ¹⁰⁸Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- ¹⁰⁹Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland
- ¹¹⁰Faculty of Medicine, Fundacion Jimenez Diaz, CIBERES, Autonoma University of Madrid, Madrid, Spain
- ¹¹¹Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK
- ¹¹²The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
- ¹¹³PROMISE Department, University of Palermo, Palermo, Italy
- ¹¹⁴Department of Pediatrics, Hospital Nacional de Niños, San José, Costa Rica
- ¹¹⁵Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic
- ¹¹⁶Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino and Mauriziano Hospital, Torino, Italy
- ¹¹⁷Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
- ¹¹⁸Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark
- ¹¹⁹Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
- ¹²⁰Department of Immunoallergology, Cova da Beira University Hospital Centre, Covilhã, Portugal
- ¹²¹The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
- ¹²²Department of General ORL, H&NS, Medical University of Graz, ENT-University Hospital Graz, Graz, Austria
- ¹²³Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece
- ¹²⁴International Primary Care Respiratory Group International Primary Care Respiratory Group, (IPCRG), Aberdeen, Scotland
- ¹²⁵Airways Disease Section, National Heart and Lung Institute (NHLI), Imperial College London and Royal Brompton Hospital, London, UK
- ¹²⁶Faculty of Medicine, Institute of Clinical Medicine and Institute of Health Sciences, Vilnius University, Vilnius, Lithuania
- ¹²⁷European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium
- ¹²⁸Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy
- ¹²⁹Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy
- ¹³⁰CNR Institute for Biomedical Research and Innovation, Palermo, Italy
- ¹³¹Sotiria Hospital, Athens, Greece
- ¹³²Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- ¹³³International Primary Care Respiratory Group IPCRG, Aberdeen, Scotland
- ¹³⁴Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
- ¹³⁵Department of Pulmonology, Celal Bayar University, Manisa, Turkey
- ¹³⁶Universidad Nacional de Villa Maria, Universidad Católica de Córdoba, Córdoba, Argentina
- ¹³⁷University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia
- ¹³⁸Transylvania University Brasov, Brasov, Romania

Correspondence

Jean Bousquet, CHU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.

Email: jean.bousquet@orange.fr

ORCID

- Cezmi A. Akdis  <https://orcid.org/0000-0001-8020-019X>
- Oliver Pfaar  <https://orcid.org/0000-0003-4374-9639>
- Kari C. Nadeau  <https://orcid.org/0000-0002-2146-2955>
- Thomas Eiwegger  <https://orcid.org/0000-0002-2914-7829>
- Claus Bachert  <https://orcid.org/0000-0003-4742-1665>
- Karl-Christian Bergmann  <https://orcid.org/0000-0002-0306-9922>
- Mateo Bonini  <https://orcid.org/0000-0002-3042-0765>
- Louis-Philippe Boulet  <https://orcid.org/0000-0003-3485-9393>
- Victoria Cardona  <https://orcid.org/0000-0003-2197-9767>
- Thomas Casale  <https://orcid.org/0000-0002-3149-7377>
- Mübeccel Akdis  <https://orcid.org/0000-0003-0554-9943>
- Alvaro A. Cruz  <https://orcid.org/0000-0002-7403-3871>

Wytse J. Fokkens  <https://orcid.org/0000-0003-4852-229X>
 Maia Gotua  <https://orcid.org/0000-0003-2497-4128>
 Tari Haahtela  <https://orcid.org/0000-0003-4757-2156>
 Eckard Hamelmann  <https://orcid.org/0000-0002-2996-8248>
 Dmitry Kudlay  <https://orcid.org/0000-0003-1878-4467>
 Michael Levin  <https://orcid.org/0000-0003-2439-7981>
 Desiree Larenas-Linnemann  <https://orcid.org/0000-0002-5713-5331>
 Mario Morais-Almeida  <https://orcid.org/0000-0003-1837-2980>
 Ken Ohta  <https://orcid.org/0000-0001-9734-4579>
 Nikos G. Papadopoulos  <https://orcid.org/0000-0002-4448-3468>
 Gianni Passalacqua  <https://orcid.org/0000-0002-5139-3604>
 Vincenzo Patella  <https://orcid.org/0000-0001-5640-6446>
 Joaquin Sastre  <https://orcid.org/0000-0003-4689-6837>
 Peter-Valentin Tomazic  <https://orcid.org/0000-0001-6445-4800>
 Sanna Toppila-Salmi  <https://orcid.org/0000-0003-0890-6686>
 Gary W. K. Wong  <https://orcid.org/0000-0001-5939-812X>
 Torsten Zuberbier  <https://orcid.org/0000-0002-1466-8875>
 Ioana Agache  <https://orcid.org/0000-0001-7994-364X>

REFERENCES

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5: 536–544.
2. Bousquet J, Akdis C, Jutel M, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. *Allergy.* 2020. <https://doi.org/10.1111/all.14302>
3. Wadhwa RK, Wadhwa P, Gaba P, et al. Variation in COVID-19 hospitalizations and deaths across New York City boroughs. *JAMA.* 2020;323(21):2192.
4. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA.* 2020;323(16):1574.
5. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of Covid-19: a systemic review and meta-analysis. *J Med Virol.* 2020. <https://doi.org/10.1002/jmv.25889>
6. Zhang JJ, Cao YY, Dong X, et al. Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2. *Allergy.* 2020. <https://doi.org/10.1111/all.14316>
7. Dong X, Cao YY, Lu XX, et al. Eleven Faces of Coronavirus Disease 2019. *Allergy.* 2020. <https://doi.org/10.1111/all.14289>
8. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020. <https://doi.org/10.1016/j.jaci.2020.04.006>
9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized With COVID-19 in the New York City area. *JAMA.* 2020;323(20):2052-2059.
10. Parodi SM, Liu VX. From Containment to Mitigation of COVID-19 in the US. *JAMA.* 2020;323(15):1441.
11. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1–30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(15):458-464.
12. Docherty A, Harrison E, Green C, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <https://doi.org/10.1101/2020.04.23.20076042>
13. Collaborative TO, Williamson E, Walker A, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *MedRxiv.* 2020. <https://doi.org/10.1101/2020.05.06.20092999>. <https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1.full.pdf>
14. Morais-Almeida M, Pit e H, Aguiar R, Anotegui I, Bousquet J. Asthma and the COVID-19 pandemic: literature review. *Int Allergy Immunol.* 2020; <https://doi.org/10.1159/000509057>
15. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. *Antimicrob Agents Chemother.* 2020. <https://doi.org/10.1128/AAC.00819-20>
16. Wu X, Nethery R, Sabath B, Braun D, Dominici F. Exposure to air pollution and COVID-19 mortality in the United States: A nationwide cross-sectional study. medRxiv and. *BioRxiv.* 2020. <https://www.medrxiv.org/content/10.1101/2020.04.05.20054502v2>
17. Jackson D, Busse W, Bacharier L, et al. Association of respiratory allergy, asthma and expression of the SARS-CoV-2 receptor, ACE2. *J Allergy Clin Immunol.* 2020; <https://doi.org/10.1164/rccm.202003-0821OC>
18. Peters MC, Sajuthi S, Deford P, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. *Am J Respir Crit Care Med.* 2020. <https://doi.org/10.1164/rccm.202003-0821OC>
19. Sajuthi S, DeFord P, Jackson N, et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. *bioRxiv.* 2020. <https://doi.org/10.1101/2020.04.09.034454>